Inhibition by the anti-mitotic drug doxorubicin of platelet-activating-factor-induced late eosinophil accumulation in rats.

[1]  S. Johnson,et al.  Anthracyclines in haematology: preclinical studies, toxicity and delivery systems. , 1997, Blood reviews.

[2]  P. O'Byrne,et al.  Allergen-induced increases in IL-5 receptor alpha-subunit expression on bone marrow-derived CD34+ cells from asthmatic subjects. A novel marker of progenitor cell commitment towards eosinophilic differentiation. , 1997, The Journal of clinical investigation.

[3]  P. O'Byrne,et al.  Bone marrow progenitors in allergic airways diseases: studies in canine and human models. , 1997, International archives of allergy and immunology.

[4]  S. Tohma,et al.  Eosinophil adhesion to human bronchial epithelial cells: regulation by cytokines. , 1997, International archives of allergy and immunology.

[5]  C. Bachert,et al.  Direct demonstration of delayed eosinophil apoptosis as a mechanism causing tissue eosinophilia. , 1997, Journal of immunology.

[6]  J. Lammers,et al.  Mechanisms involved in eosinophil migration. Platelet‐activating factor‐induced Chemotaxis and interleukin‐5‐induced chemokinesis are mediated by different signals , 1996, Journal of leukocyte biology.

[7]  M. Yamakido,et al.  Effects of a PAF antagonist, Y-24180, on bronchial hyperresponsiveness in patients with asthma. , 1995, American journal of respiratory and critical care medicine.

[8]  A. Kapp,et al.  Activation of the respiratory burst in human eosinophils by chemotaxins requires intracellular calcium fluxes. , 1995, The Journal of investigative dermatology.

[9]  P. O'Byrne,et al.  Allergen-induced changes in bone marrow progenitors and airway responsiveness in dogs. , 1995, International archives of allergy and immunology.

[10]  V. Praloran,et al.  PAF and haematopoiesis: III. Presence and metabolism of platelet-activating factor in human bone marrow. , 1995, Biochimica et biophysica acta.

[11]  V. Praloran,et al.  PAF and haematopoiesis. IV. Modifications of spleen and thymus PAF contents after a single dose of the chemotherapeutic drug 5-fluorouracil in mice. , 1995, Cancer letters.

[12]  G. Zimmerman,et al.  Platelet-activating factor: a phospholipid autacoid with diverse actions. , 1993, Journal of lipid research.

[13]  M. Martins,et al.  Generation of an eosinophilotactic activity in the pleural cavity of platelet-activating factor-injected rats. , 1991, The Journal of pharmacology and experimental therapeutics.

[14]  F. Zunino,et al.  DNA topoisomerase II as the primary target of anti-tumor anthracyclines. , 1990, Anti-cancer drug design.

[15]  R. Borojevic,et al.  Extramedullar proliferation of eosinophil granulocytes in chronic schistosomiasis mansoni is mediated by a factor secreted by inflammatory macrophages , 1990, Infection and immunity.

[16]  J. Verhagen,et al.  Platelet-activating factor induces leukotriene C4 synthesis by purified human eosinophils. , 1987, Prostaglandins.

[17]  H. Kita,et al.  In Vitro: Synergistic Effects of Platelet-activating Factor and Eosinophil-active Cytokines , 1997 .

[18]  V. Praloran,et al.  PAF and Haematopoiesis. I. 5-Fluoro-Uracil Induces PAF Production in Haematopoietic Organs of Rats , 1994, Mediators of inflammation.

[19]  M. Martins,et al.  Eosinophil granulocyte proliferation induced by an intermediate factor generated in the pleural cavity of rats injected with platelet-activating factor-acether. , 1993, International archives of allergy and immunology.

[20]  A. Kataura,et al.  Role of capsaicin-sensitive sensory nerve reflexes in guinea pig model of nasal allergy. , 1993, International archives of allergy and immunology.

[21]  G. Schuurhuis,et al.  Doxorubicin (adriamycin): a critical review of free radical-dependent mechanisms of cytotoxicity. , 1990, Pharmacology & therapeutics.